Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash & Current Investments (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Cash & Current Investments data on record, last reported at $343.1 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 33.04% year-over-year to $343.1 million; the TTM value through Dec 2025 reached $343.1 million, up 33.04%, while the annual FY2025 figure was $343.1 million, 33.04% up from the prior year.
  • Cash & Current Investments reached $343.1 million in Q4 2025 per TNGX's latest filing, up from $94.5 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $506.1 million in Q3 2021 and bottomed at $428000.0 in Q2 2025.
  • Average Cash & Current Investments over 5 years is $250.4 million, with a median of $307.7 million recorded in 2024.
  • Peak YoY movement for Cash & Current Investments: skyrocketed 212683.58% in 2021, then crashed 99.87% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $487.5 million in 2021, then dropped by 24.9% to $366.1 million in 2022, then crashed by 81.62% to $67.3 million in 2023, then surged by 283.32% to $257.9 million in 2024, then soared by 33.04% to $343.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $343.1 million in Q4 2025, $94.5 million in Q3 2025, and $428000.0 in Q2 2025.